DCM
JBIO

Driehaus Capital Management’s Jade Biosciences JBIO Stock Holding History

Driehaus Capital Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-635,498
Closed -$8.93M – 363
2026
Q1 		$8.93M Sell
635,498
-251,681
-28% -$3.64M 0.07% 273
2025
Q4 		$13.7M Sell
887,179
-368,619
-29% -$4.32M 0.09% 254
2025
Q3 		$10.8M Hold
1,255,798
– – 0.08% 269
2025
Q2 		$12.5M Buy
+1,255,798
New +$42.7M 0.1% 232
2024
Q2 		– Sell
-22,714
Closed -$23.5M – 370
2024
Q1 		$23.5M Sell
22,714
-7,521
-25% -$5.74M 0.23% 124
2023
Q4 		$23.9M Sell
30,235
-3,697
-11% -$1.88M 0.29% 111
2023
Q3 		$16.1M Sell
33,932
-185
-0.5% -$100K 0.21% 156
2023
Q2 		$20.5M Buy
+34,117
New +$21.8M 0.26% 123
2022
Q4 		– Sell
-1,339
Closed -$777K – 351
2022
Q3 		$777K Buy
+1,339
New +$894K 0.01% 310

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Driehaus Capital Management's JBIO Position: Q2 2026 in Review

Driehaus Capital Management sold out of Jade Biosciences (JBIO) in Q2 2026, closing a stake of 635,498 shares — an estimated $8.93M sold.

Driehaus Capital Management first reported a position in JBIO in Q3 2022 and held it in 9 quarters. The position peaked at $23.9M in Q4 2023. 154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Driehaus Capital Management reported no remaining Jade Biosciences position as of Q2 2026 after selling out during the quarter.
  • Driehaus Capital Management sold 635,498 Jade Biosciences shares in Q2 2026, an estimated $8.93M.
  • Driehaus Capital Management first reported a position in Jade Biosciences in Q3 2022 and held it in 9 quarters.
  • Driehaus Capital Management's Jade Biosciences position peaked at $23.9M in Q4 2023.
  • 154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Driehaus Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.